Beyond its antiviral capabilities, emerging research highlights SLFN11’s role in enhancing cancer cell sensitivity to DDAs, making it a potential biomarker for predicting treatment outcomes in ovarian, lung, and colorectal cancers (Zoppoli et al., 2012; Gardner et al., 2017; Deng et al., 2015). The gene discussed is SLFN11; the disease is cancer.